

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231 on this 29th day of December, 2000.

By

[Signature]
(Signature of person mailing)
ROY F. WALDRON

(Typed or printed name of person)

RECEIVED

JAN 09 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: J. W. Coe et al.

Examiner: B. Coleman

SER. NO.: 09/402,010

Group Art Unit: 1624

FILING DATE: September 28, 1999

TITLE: ARYL FUSED AZAPOLYCYCLIC
COMPOUNDS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

This is responsive to the Office Action mailed September 29, 2000, a Response to which was due on December 29, 2000. Accordingly, this response is timely.

Applicants request the following amendments to the application be entered.

IN THE ABSTRACT

at page 80, line 9, "R³ and n" are deleted and -- and R³ -- is substituted therefor;
at page 80, line 12, "are claimed" is deleted.

IN THE SPECIFICATION

at page 1, line 5, add the following text:

-- This application is a national stage entry under 35 U.S.C. § 371 of PCT/IB98/01813, filed November 13, 1998 which claims the benefit of U.S. Provisional Application Ser. No. 60/070,245, filed December 31, 1997. --

at page 1, line 13, delete "amylotropic" and substitute therefor -- amyotrophic --;
at page 1, line 15, delete "supramuscular" and substitute therefor -- supranuclear --;
at page 1, line 17, delete "barbituates" and substitute therefor -- barbiturates --;
at page 3, line 22, "piperizine, -N-(C₁-C₆)alkylpiperizine" is deleted and -- piperazine, -N-(C₁-C₆)alkylpiperazine -- is substituted therefor;